Mohammad A. Shehab

Kuwait City, KU 47060, Kuwait

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.

The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.

Journal: Journal of Crohn's & colitis

Published: June 26, 2026

Osteoactivin/GPNMB as a candidate biomarker of diabetic nephropathy in type 2 diabetes: associations with angiogenic and kidney injury biomarkers.

Osteoactivin/GPNMB as a candidate biomarker of diabetic nephropathy in type 2 diabetes: associations with angiogenic and kidney injury biomarkers.

Journal: Frontiers in endocrinology

Published: June 14, 2026

Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.

Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.

Journal: Crohn's & colitis 360

Published: April 17, 2026

Epidemiology and clinical profile of inflammatory bowel disease in Kuwait: a nationwide tertiary care (SEEF-IBD) study.

Epidemiology and clinical profile of inflammatory bowel disease in Kuwait: a nationwide tertiary care (SEEF-IBD) study.

Journal: BMC gastroenterology

Published: April 07, 2026

From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review.

From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review.

Journal: Biomedicines

Published: February 27, 2026

Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials.

Biologics and small molecules for perianal Crohn's disease: a systematic review and meta-analyses of randomized placebo-controlled trials.

Journal: Inflammatory bowel diseases

Published: February 14, 2026

A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence.

A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence.

Journal: The American journal of case reports

Published: January 16, 2026

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study.

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study.

Journal: Journal of clinical medicine

Published: November 08, 2025

Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study.

Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study.

Journal: Frontiers in pharmacology

Published: October 23, 2025

High-Dose Upadacitinib Maintenance Therapy for Refractory Crohn's Disease: A Case Series and Review of the Literature.

High-Dose Upadacitinib Maintenance Therapy for Refractory Crohn's Disease: A Case Series and Review of the Literature.

Journal: Case reports in gastroenterology

Published: August 18, 2025

Associations between Patients' Demographics and Chronic Medication Utilization in Internal Medicine: Cross-sectional Study.

Associations between Patients' Demographics and Chronic Medication Utilization in Internal Medicine: Cross-sectional Study.

Journal: Journal of research in pharmacy practice

Published: August 14, 2025

Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors' Reply.

Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: August 06, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026